Business · Companies · 2 hrs ago
Celltrion posts record quarterly results as new drug sales surge
South Korean drugmaker Celltrion reported record third-quarter results, with sales of 1.5755 trillion won and operating profit of 525.3 billion won.
Both figures were much higher than a year earlier, as sales of newer products grew quickly.
Five newer product groups brought in 388 billion won, up 335% from the same quarter last year.
Their growing share of sales helped lift the operating profit margin to 33.3%, from 29.3% a year earlier.
Four brokerages raised their share price targets and kept their ratings at “buy,” citing stronger sales and expected profit growth.
Analysts expect new products to support further growth next year, though forecasts differ between firms.
One outstanding question is whether increased US prescriptions for Zymfentra will translate into higher sales, after its third-quarter revenue fell from the previous quarter.
Celltrion reported record quarterly results, with third-quarter revenue of 1.5755 trillion won and operating profit of 525.3 billion won.
Revenue rose 53.1% and operating profit rose 74.3% from a year earlier, beating market estimates.
Sales of five new products launched since last year reached 388 billion won, up 335% year on year.
Higher sales of profitable products helped lift the operating margin to 33.3%, from 29.3% a year earlier.
Brokerages raised their price targets, citing expectations for continued growth, while one analyst said Zymfentra’s sales performance remained a point to watch.
- Who
- Celltrion, a South Korean biopharmaceutical company.
- What
- It reported record third-quarter results as new-product sales surged.
- When
- The results were for the third quarter of 2026 and were reported on October 28, 2026.
- Where
- Not stated
- Why
- Sales of new, higher-margin products grew, improving the company’s product mix and profitability.
This story does not have two clearly opposing sides.
Celltrion recorded revenue of 1.5755 trillion won and operating profit of 525.3 billion won.
Celltrion launched Omlyclo in the United States, according to Daishin Securities researcher Hong Ga-hye.
Reports on Celltrion’s results said brokerages raised their price targets.
- Third-quarter revenue
- 1.5755 trillion won
- Third-quarter operating profit
- 525.3 billion won
- Year-on-year revenue growth
- 53.1%
- Year-on-year operating profit growth
- 74.3%
- Five new products’ combined sales
- 388 billion won, up 335% year on year
- Operating margin
- 33.3%, up 4.0 percentage points year on year
What people are saying
Growth in new products and the competitiveness of direct sales are being confirmed in the results
We raised our earnings estimates to reflect accelerating growth in new-product sales, and judge that the visibility of next year's earnings growth is improving
Omlyclo has secured supply contracts with large medical companies and listing as a preferred drug with pharmacy benefit managers since its U.S. launch in October, and initial orders are also exceeding expectations
Celltrion is expected to have overwhelming growth and profitability compared with its competitors, so a structural premium in its valuation is warranted